Biodesix, Inc.
Biodesix is a leading diagnostic solutions company dedicated to transforming patient care and improving outcomes through personalized diagnostics. They provide advanced diagnostic tests and custom development services, supporting clinical decisions to expedite personalized care for lung disease patients. Their mission is to conquer patient diseases with personalized diagnostics, and their vision is to transform standard of care through innovative testing and research. The company emphasizes a culture of impact, excellence, and teamwork, and has received numerous recognitions including Top Workplaces and industry awards. Biodesix operates highly accredited laboratories and a manufacturing facility, with a focus on molecular and proteomic technologies, clinical studies, and diagnostic development. They serve biopharmaceutical, life sciences, and research institutions, and are committed to making their tests accessible through comprehensive billing and reimbursement programs.
Industries
Nr. of Employees
medium (51-250)
Biodesix, Inc.
919 W Dillon Road Louisville, CO 80027
Patents
Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
US-12230398-B2
View DetailsApparatus and method for identification of primary immune resistance in cancer patients
US-12094587-B2
View DetailsPredictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
US-11710539-B2
View DetailsClassifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
US-11621057-B2
View Details
Predictive test for patient benefit from antibody drug blocking ligand activation of the T-cell programmed cell death 1 (PD-1) checkpoint protein and classifier development methods
US-12230398-B2
View DetailsApparatus and method for identification of primary immune resistance in cancer patients
US-12094587-B2
View DetailsPredictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
US-11710539-B2
View DetailsClassifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
US-11621057-B2
View DetailsProducts
Blood-based lung nodule risk assessment tests (proteomic classifier)
Blood-based proteomic tests intended to classify the malignancy risk of pulmonary nodules and support clinical decision making around surveillance versus invasive procedures.
Blood-based tumor mutation testing (targeted genomic test)
Targeted blood-based genomic tests to detect actionable tumor mutations to inform targeted therapy eligibility and clinical trial enrollment for non-small cell lung cancer.
Host immune-response classifier (prognostic/predictive immune profiling test)
A blood-based host immune classifier that provides predictive and prognostic information to inform immunotherapy and combination treatment strategies across stages of disease.
Blood-based lung nodule risk assessment tests (proteomic classifier)
Blood-based proteomic tests intended to classify the malignancy risk of pulmonary nodules and support clinical decision making around surveillance versus invasive procedures.
Blood-based tumor mutation testing (targeted genomic test)
Targeted blood-based genomic tests to detect actionable tumor mutations to inform targeted therapy eligibility and clinical trial enrollment for non-small cell lung cancer.
Host immune-response classifier (prognostic/predictive immune profiling test)
A blood-based host immune classifier that provides predictive and prognostic information to inform immunotherapy and combination treatment strategies across stages of disease.
Services
End-to-end services covering translational research, biomarker discovery, assay design, analytical and clinical validation, and commercialization support for diagnostic tests.
Laboratory testing and longitudinal monitoring services for clinical development including cfDNA/cfRNA testing, ddPCR, NGS profiling, targeted and untargeted proteomics, and sample logistics.
Support for translational research projects including biomarker discovery, assay validation, clinical sample testing, and operational support for research studies.
Design, manufacture, and supply of specimen collection kits, plus tracking, returns logistics, and chain-of-custody management to support clinical trials and diagnostic services.
End-to-end services covering translational research, biomarker discovery, assay design, analytical and clinical validation, and commercialization support for diagnostic tests.
Laboratory testing and longitudinal monitoring services for clinical development including cfDNA/cfRNA testing, ddPCR, NGS profiling, targeted and untargeted proteomics, and sample logistics.
Support for translational research projects including biomarker discovery, assay validation, clinical sample testing, and operational support for research studies.
Design, manufacture, and supply of specimen collection kits, plus tracking, returns logistics, and chain-of-custody management to support clinical trials and diagnostic services.
Expertise Areas
- Diagnostic assay development
- Liquid biopsy and ctDNA/cfRNA testing
- Proteomics and biomarker discovery
- Clinical trial sample testing and support
Key Technologies
- Droplet digital PCR (ddPCR)
- Next-generation sequencing (NGS)
- Liquid chromatography–tandem mass spectrometry (LC-MS/MS)
- MALDI-TOF mass spectrometry
News & Updates
Discussion on how Biodesix diagnostic tests are changing lung cancer detection and treatment, June 2024.
Insights from Gary Pestano on digital PCR biomarker solutions, April 2025.
Recognition of Biodesix as a great place to work, June 2024.
Using a Blood Biomarker to Distinguish Benign From Malignant Pulmonary Nodules - A Subgroup Analysis
Published in CHEST Journal, December 2023, analyzing blood biomarkers for lung nodules.
Recognition by The Healthcare Technology Report, ranking #32.
Named by The Denver Post as a top workplace, June 2024.
Discussion on how Biodesix diagnostic tests are changing lung cancer detection and treatment, June 2024.
Insights from Gary Pestano on digital PCR biomarker solutions, April 2025.
Recognition of Biodesix as a great place to work, June 2024.
Using a Blood Biomarker to Distinguish Benign From Malignant Pulmonary Nodules - A Subgroup Analysis
Published in CHEST Journal, December 2023, analyzing blood biomarkers for lung nodules.
Recognition by The Healthcare Technology Report, ranking #32.
Named by The Denver Post as a top workplace, June 2024.